← Ablatotech Signals
InfectiousDisease SignalsArticle

A putative therapeutic target in chronic hepatitis C: P05783

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
June 24, 2026 · Lead editor: InfectiousDiseaseEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P05783 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in chronic hepatitis C.

# Signals Article: Putative Target P05783 for Chronic Hepatitis C

Background

Chronic hepatitis C virus (HCV) infection is a significant global health issue, leading to severe liver diseases, including cirrhosis and hepatocellular carcinoma. Despite the advent of highly effective direct-acting antiviral therapies, a subset of patients still experiences treatment failure or reinfection. Identifying novel therapeutic targets is essential for improving treatment outcomes and developing strategies for eradication. The putative target candidate P05783, identified through expression profiling studies, may provide a promising avenue for therapeutic intervention in chronic hepatitis C. However, there are currently no registered Phase 1 or higher clinical programs targeting this candidate, indicating a potential gap in the translation of this target into clinical applications.

Data-mining rationale

The identification of P05783 as a putative target was achieved by cross-referencing UniProt's reviewed human entries for "chronic hepatitis C" against 40 microarray datasets available in the NCBI GEO database, including GDS:200085550, GDS:200085548, GDS:200085547, GDS:200085546, and GDS:200153565. The candidate was found to be expressed in these studies, yet it lacks a corresponding clinical development program, highlighting the need for further investigation into its therapeutic potential.

Why prior analyses may have missed this

Prior analyses may have overlooked the significance of P05783 due to several factors. Many of the GEO datasets utilized in the initial examination predate the adoption of modern empirical-Bayes statistical methods, such as limma, which are essential for accurately assessing differential gene expression while controlling for multiple testing. The absence of rigorous statistical validation may have led to the underappreciation of the candidate's relevance in the context of chronic HCV infection. A re-analysis of these datasets using contemporary statistical approaches could yield new insights into the expression patterns and potential roles of P05783.

Reasoning for further validation

To further explore the therapeutic potential of the putative target P05783, the following experimental approaches are recommended: 1. **Re-analyze GEO Datasets**: Conduct a re-analysis of the matched GEO datasets using the limma package, applying the Benjamini-Hochberg method for false discovery rate (FDR) correction with a threshold of < 0.05 to accurately identify differentially expressed genes. 2. **Validate Differentially Expressed Genes**: Perform quantitative PCR (qPCR) on the top differentially expressed genes in an independent cohort to validate the findings from the re-analysis and confirm the expression levels of P05783. 3. **Check Tissue Specificity**: Investigate the tissue specificity of P05783 using resources such as GTEx (Genotype-Tissue Expression) and the Human Protein Atlas to understand its expression patterns across various human tissues. 4. **Pathway Context Analysis**: Utilize STRING and OmniPath databases to assess the biological pathways in which P05783 is involved, providing context for its potential role in chronic HCV pathogenesis. 5. **Assess Druggability**: If validated, evaluate the druggability of P05783 through databases such as DGIdb and ChEMBL to explore potential small molecule inhibitors or therapeutic agents targeting this candidate.

References

  • [UniProt: P05783](https://www.uniprot.org/uniprot/P05783) - Entry for the putative target candidate.
  • [GDS:200085550](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200085550) - Microarray dataset related to chronic hepatitis C.
  • [GDS:200085548](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200085548) - Another relevant microarray dataset for analysis.
  • [GDS:200085547](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200085547) - Additional dataset for chronic hepatitis C research.
  • [GDS:200085546](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200085546) - Further dataset contributing to the analysis.
  • [GDS:200153565](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200153565) - Another dataset relevant to the study of chronic hepatitis C.

References

  1. UniProtKB. Entry P05783. The UniProt Consortium. [link]
  2. UniProtKB. Entry Q14973. The UniProt Consortium. [link]
  3. UniProtKB. Entry P42224. The UniProt Consortium. [link]
  4. UniProtKB. Entry P11226. The UniProt Consortium. [link]
  5. UniProtKB. Entry Q9BYM8. The UniProt Consortium. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications